SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!
Welcome to the International Immuno-Oncology Biomarker Working Group on Breast Cancer
  • Registration
  • Contact Us
  • LOGIN

International TILS Working Group

  • HOME
    • Membership
    • Funding
    • Who we are
    • Mission
    • Composition of the group
    • Core group
    • Contact Us
    • FAQs
  • RESEARCH & EDUCATION
    • General
      • What are TILs and why are they important ?
      • Presentations
      • Literature Update
      • Q&A on TIL-assessment
      • Researcher Resources
      • Pathology Resources
    • Train yourself !Learn to score TILS
      • … Tutorial Videos
      • … in invasive breast cancer
      • … in solid tumors and in the metastatic setting
      • … in residual disease after treatment
      • … in DCIS
      • … Reference images and pitfalls
    • Ongoing Projects
      • Incorporation of TILs in the Residual Cancer Burden Index
      • Artificial Intelligence / Deep Learning / Machine Learning approaches to TIL-assessment
      • Coming soon: Machine Learning & Clinical Trials
    • Working Groups
      • … on TILs and DCIS
      • … on TILs and Machine Learning Algorithms
      • … on TILs in residual Disease
      • .. on TILs in solid tumors other than Breast Cancer
      • … on TILs in mouse models
  • BLOG
  • NEWS
  • PARTNERS & CAREERS
  • MEETINGS
Teach yourself to score TILs!
  • Home
  • Online TIL and Prognosis Tool

Online TIL and Prognosis Tool

Retrospective analyses from distinct clinical trials have suggested that host anti-tumor immunity as measured by tumor infiltrating lymphocytes (TILs) is important for the outcomes of primary triple negative breast cancer (TNBC), but the clinical utility of TILs in day-to-day management of primary TNBC is still limited.

A pooled analysis was conducted of the clinical trials that have investigated the TILs in TNBC patients treated by anthracyclines-based (A) chemotherapy regimens in order to gain a robust understanding of the prognostic value of TILs in this setting. Eligible studies were those randomized clinical trials that have evaluated the prognostic associations of TILs in patients diagnosed with early stage TNBC treated with A or A plus taxanes (A+T).

In a multivariable analysis adjusted for age, nodal status, tumor size and chemotherapy regimen, stromal TILs significantly added independent prognostic information both for IDFS and OS. This large pooled individual patient data analysis confirms the strong prognostic role of stromal TILS in primary TNBC treated with A or A+T. TILs can be useful for predicting patients’ prognosis and for stratification in future clinical trials enrolling TNBC patients. A large proportion of primary TNBC patients seem to have pre-existing immunity making them rational candidates for immunotherapy clinical trials.

Therefore, this tool will help you determine the prognosis of your patient wherein you just have to include as variables TIls, nodal status, age and tumor size.

Access Prognosis Tool here

You can find detailed instructions on how to use the tool here and here.

Overview Articles

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

Categories

  • New
  • TILs in machine learning algorithms

Topics discussed

Follow me on Twitter

Tweets by @TILsWorkGroup

Blog Archive

  • February 2019
  • January 2018
Website powered by Copyright © 2022 - 2022. All rights reserved.

Website general Terms & Conditions

info@tilsinbreastcancer.org

TOP